Constantine Kosmas
Cardiovascular Disease · Astoria, NYNPI 1407855075
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,000 of the $14,300 with a category attached, or 62.9%. Amarin Pharma, Inc. accounts for 80.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $11,980 and has fallen 99.5% since, to $63 in 2025.
Across 142 payments — averaging $100.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$12K
- Boehringer Ingelheim$665
- Johnson & Johnson$589
- Novartis$463
- Amgen$329
- E.r. Squibb & Sons, L.L.C.$222
- plus $528 from 12 others
What the payments were for
- Speaking & faculty fees$9,00063%
- Travel & lodging$1,71912%
- Food & beverage$3,58025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 34 | $11,504 |
| Boehringer Ingelheim | 6 | $665 |
| Johnson & Johnson | 26 | $589 |
| Novartis | 23 | $463 |
| Amgen | 15 | $329 |
| E.r. Squibb & Sons, L.L.C. | 12 | $222 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Merck | 4 | $77 |
| AstraZeneca | 4 | $72 |
| Bayer | 3 | $67 |
| Pfizer | 2 | $63 |
| Althera Pharmaceuticals LLC | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Braemar Manufacturing, LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,300 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $39,181 |
| EntrestoSacubitril/Valsartan | 28 | $31,889 |
| VascepaIcosapent Ethyl | 32 | $13,366 |
| Atorvastatin Calcium | 133 | $1,980 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 11 | $1,243 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 16 | $1,066 |
| Valsartan | 26 | $846 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 18 | $792 |
| Metoprolol Succinate | 33 | $687 |
| Rosuvastatin Calcium | 35 | $675 |
| Ezetimibe | 13 | $609 |
| Bisoprolol Fumarate | 13 | $497 |
| Losartan Potassium | 39 | $449 |
| Amlodipine Besylate | 58 | $407 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 13 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $665 | $39,18148 claims |
| NovartisEntresto | $463 | $31,88928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Astoria
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.